Besponsa
Showing 1 - 17 of 17
BESPONSA Injection 1 mg Special Investigation
Active, not recruiting
- Acute Lymphocytic Leukemia
-
Tokyo, JapanPfizer
Jun 20, 2023
Besponsa Post Marketing Surveillance Study
Active, not recruiting
- Hematologic Maligmancy
- Inotuzumab ozogamicin
-
Seoul, Korea, Republic ofPfizer
Oct 10, 2022
Acute Lymphoblastic Leukemia Trial (inotuzumab ozogamicin)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- inotuzumab ozogamicin
- (no location specified)
Jan 6, 2023
Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That
Not yet recruiting
- Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Inotuzumab Ozogamicin
- (no location specified)
Nov 3, 2022
ACUTE LYMPHOBLASTIC LEUKEMIA Trial (Inotuzumab ozogamicin, ALLR3)
Not yet recruiting
- ACUTE LYMPHOBLASTIC LEUKEMIA
- Inotuzumab ozogamicin
- ALLR3
- (no location specified)
Feb 17, 2023
Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia Trial in Chicago (Inotuzumab ozogamicin,
Recruiting
- Lymphoblastic Leukemia
- +2 more
- Inotuzumab ozogamicin
- +7 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
May 16, 2022
B-cell Acute Lymphoblastic Leukemia Trial in United States (Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Inotuzumab ozogamicin
- +6 more
-
Nashville, Tennessee
- +3 more
Aug 14, 2022
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL Trial in Boston (Venetoclax, Dexamethasone, Inotuzumab Ozogamicin)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- Venetoclax
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 19, 2021
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5
Withdrawn
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- +7 more
- Inotuzumab Ozogamicin
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 13, 2022
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Completed
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- +6 more
- Bosutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 25, 2022
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Houston (Inotuzumab
Terminated
- CD22 Positive
- +2 more
- Inotuzumab Ozogamicin
-
Houston, TexasM D Anderson Cancer Center
Mar 17, 2021
Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA Trial in Worldwide (inotuzumab
Active, not recruiting
- Leukemia
- +2 more
- inotuzumab ozogamicin-dose level 2
- Inotuzumab ozogamicin-dose level 1
-
Los Angeles, California
- +45 more
Mar 9, 2022
Acute Lymphoblastic Leukemia Trial (Tisagenlecleucel, Blinatumomab, Inotuzumab)
Withdrawn
- Acute Lymphoblastic Leukemia
- Tisagenlecleucel
- +2 more
- (no location specified)
Jul 7, 2020
Leukemia, Acute Lymphoblastic Trial in Worldwide (Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab
Recruiting
- Leukemia, Acute Lymphoblastic
- Omitted Doxorubicin
- +5 more
-
Brussels, Belgium
- +100 more
Dec 12, 2022
Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia
Terminated
- Acute Lymphoblastic Leukemia in Remission
- +2 more
- Cyclophosphamide
- +12 more
-
Houston, TexasM D Anderson Cancer Center
Mar 18, 2021
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma Trial in Houston (biological, drug, other)
Recruiting
- B Acute Lymphoblastic Leukemia
- B Lymphoblastic Lymphoma
- Blinatumomab
- +12 more
-
Houston, TexasM D Anderson Cancer Center
Feb 21, 2021
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial in
Recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +3 more
- Biospecimen Collection
- +11 more
-
Birmingham, Alabama
- +152 more
Jan 30, 2023